Immix Biopharma Business Summary

Immix Biopharma, Inc. (IMMX) is a clinical-stage biopharmaceutical company primarily focused on developing Tissue-Specific Therapeutics (TST) and chimeric antigen receptor (CAR) T-cell therapies for oncology, hematologic malignancies, and autoimmune diseases. The company operates as a pre-revenue entity, with a business model centered on the clinical advancement of its proprietary pipeline to secure future revenue through product commercialization, strategic out-licensing agreements, and milestone-based partnerships. Its primary business segments are divided between its CAR-T platform, led by NXC-201—a BCMA-targeted therapy recently granted FDA Breakthrough Therapy Designation for relapsed/refractory AL amyloidosis—and its TME Normalization technology, featuring the asset IMX-110 for solid tumors. Immix Biopharma competes directly with oncology and cell therapy developers such as Jazz Pharmaceuticals, Pliant Therapeutics, RAPT Therapeutics, and Moderna, positioning itself as a specialized leader in the orphan disease space by targeting indications with no current FDA-approved treatments for relapsed populations. The company was co-founded by CEO Dr. Ilya Rachman, a physician-scientist with a pedigree from UCLA and Cedars-Sinai, alongside Sean Senn and Scientific Co-Founder Dr. Vladimir Torchilin, a world-renowned expert in drug delivery. The leadership team is bolstered by CFO Gabriel Morris, a former investment banker, and Chief Commercial Officer Michael Grabow, who joined in late 2025 following a successful tenure at Chimerix and Amgen. Clinical operations are directed by Chief Medical Officer of Cell Therapy Dr. David Marks and Acting CMO Dr. Graham Ross. Immix is supported by a board of directors featuring industry veterans like Lead Independent Director Helen Adams and Magda Marquet, with notable institutional backing and strategic investment from firms such as Goose Capital and Mesa Verde Venture Partners.